BioSpace Collaborative

Academic/Biomedical Research
News & Jobs
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

Free Newsletters
My Subscriptions

News by Subject
News by Disease
News by Date
Search News
Post Your News

Job Seeker Login
Most Recent Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Pharm Country
  Bio NC
  Southern Pharm
  BioCanada East
  C2C Services & Suppliers™


Company Profiles

Research Store

Research Events
Post an Event
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
Get Our Industry eNewsletter FREE email:    
Clinical - Phase I
Galapagos NV (GLPG.BR) Initiates First Phase 1 Study In Cystic Fibrosis And Will Receive Milestone Payment From AbbVie (ABBV) 12/19/2014
e-Therapeutics plc Reports Progress In ETS2101 Phase 1a And Oral Dosing Studies 12/18/2014
Curis, Inc. (CRIS) Announces Dosing Of First Patient In Phase 1 Trial Of CUDC-907 In Patients With Advanced/ Relapsed Solid Tumors 12/18/2014
Inovio Pharmaceuticals (INO) Initiates DNA Immunotherapy Trial For Breast, Lung And Pancreatic Cancers 12/18/2014
ViaCyte, Inc. (Formerly Known as Novocell, Inc.) Release: Study Further Validates Cell Therapy Approach To Reverse Type 1 Diabetes 12/18/2014
Seattle Genetics, Inc. (SGEN) Initiates Phase 1b Trial Of SGN-CD33A In Combination With Frontline Standard Of Care And As Consolidation Therapy For Acute Myeloid Leukemia 12/18/2014
Dyax Corp. (DYAX)'s First-In-Human Trial For DX-2930 Conducted By Vince And Associates Clinical Research Featured In The Annals Of Allergy, Asthma & Immunology 12/18/2014
Cara Therapeutics, Inc. (CARA) Reports Positive Top-Line Data From Phase 1b Trial Of I.V. CR845 In Dialysis Patients 12/17/2014
Cerulean Pharma Inc. (CERU) Announces First Patient Dosed With CRLX301 In Phase 1/2a Trial In Advanced Solid Tumors 12/17/2014
Clementia Initiates First Prospective Natural History Study In Patients With Fibrodysplasia Ossificans Progressiva (FOP) 12/17/2014
Capstone Therapeutics (CAPS) Announces Phase 1b/2a Study Results For AEM-28 Showing Safety And Biomarker Efficacy Signals 12/16/2014
TetraLogic Pharmaceuticals (TLOG) Provides Update On Ovarian Cancer Study 12/16/2014
Hemispherx Biopharma (HEB)'s Ampligen® Provides Anti-Tumor Activity Analogous To Emerging Immune Checkpoint Inhibitors 12/16/2014
Isis Pharmaceuticals, Inc. (ISIS) Initiates Phase 1/2 Study Of ISIS-DMPK Rx In Patients With Myotonic Dystrophy Type 1 12/16/2014
Prothena Receives FDA Fast Track Designation For NEOD001, A Monoclonal Antibody For The Treatment Of Patients With AL Amyloidosis 12/16/2014
Alla Chem Completes Phase Ib/Iia Clinical Study With AV4025, An HCV NS5A Inhibitor 12/16/2014
Biocryst Pharmaceuticals (BCRX) Announces Initiation Of A Phase 1 Clinical Trial Of BCX4430 For The Treatment Of Hemorrhagic Fever Viruses 12/15/2014
Cerulean Pharma Inc. (CERU) Announces Completion Of Enrollment Of A Phase 1b/2 Study Of CRLX101 In Combination With Avastin® In Relapsed Renal Cell Carcinoma 12/15/2014
Alkermes plc (ALKS) Announces Initiation Of Clinical Study Of Extended Durations Of Aripiprazole Lauroxil For Treatment Of Schizophrenia 12/15/2014
Complexa Initiates Phase 1B Study Of CXA-10 In Acute Kidney Injury 12/15/2014
Immunomedics, Inc. (IMMU) Reports Expanded Phase 1/2 Trials Confirm Activity And Good Safety Profile Of Sacituzumab Govitecan (Immu-132) In Patients With Advanced Triple-Negative Breast Cancer 12/12/2014
Synta Pharmaceuticals (SNTA) Announces Presentation Of Results From An Investigator-Sponsored Phase 1 Trial Of Ganetespib In HER2+ Metastatic Breast Cancer At The 2014 San Antonio Breast Cancer Symposium 12/12/2014
Oncothyreon Inc. (ONTY) Announces Presentation Of Positive ONT-380 Data At San Antonio Breast Cancer Symposium 12/12/2014
Merck & Co. (MRK)'s Keytruda Shrank Tumors In Hard-To-Treat Breast Cancer Patients 12/11/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Sorafenib In Advanced Hepatocellular Carcinoma 12/11/2014
Calithera Biosciences, Inc. (CALA) Presents Novel Pharmacodynamic Assay Data Confirming Glutaminase Inhibition In Tumor Biopsy Samples From Patients Treated With CB-839 12/11/2014
Vical Incorporated (VICL) Completes Enrollment In Its Therapeutic HSV-2 Vaccine Clinical Trial 12/11/2014
Radius (RDUS) Presents RAD1901 Data At 2014 San Antonio Breast Cancer Symposium 12/11/2014
Alnylam Pharmaceuticals (ALNY) And The Medicines Company (MDCO) Announce Initiation Of Phase 1 Clinical Trial For ALN-Pcssc, A Subcutaneously Administered Investigational Rnai Therapeutic Targeting PCSK9 For The Treatment Of Hypercholesterolemia 12/11/2014
Atterocor Expands Phase 1 Trial Of ATR-101 To Additional Leading Adrenal Cancer Centers 12/11/2014
bluebird bio (BLUE) Skyrockets Almost 70% On Blood Disease Data 12/10/2014
Arno Therapeutics Doses First Patient In Expansion Stage Of Modified Phase 1/2 Trial Evaluating Onapristone In Progesterone Receptor Positive Tumors 12/10/2014
ARCA biopharma Receives FDA Orphan Drug Designation For rNAPc2 As A Potential Treatment For Ebola 12/10/2014
TiGenix Starts Phase I Trial Of Cx611 In Severe Sepsis 12/10/2014
Omni Bio Pharmaceutical Announces Encouraging Clinical Data For Use Of Alpha-1 Antitrypsin (AAT) In Steroid-Resistant Graft Versus Host Disease 12/10/2014
Alizé Pharma Announces Positive Results For AZP-531, Its Unacylated Ghrelin Analog, From Two Phase I Clinical Trials In Healthy Volunteers And Obese Subjects 12/10/2014
Can-Fite BioPharma (CFBI) To Initiate The Development Program Of Its Next Generation Drug Cf602 12/9/2014
Enteris Biopharma's Formulation Technology Enables Oral Delivery Of Cara Therapeutics, Inc. (CARA)' CR845 Peptide For Acute And Chronic Pain In Phase 1a / 1b Trial 12/9/2014
Seattle Children's Research Institute's Reprogrammed T Cell Immunotherapy Clinical Trial Boasts 85% Complete Remission Rate In Children With Relapsed Leukemia 12/9/2014
Vaccinex, Inc. Provides An Update On Its VX15/2503 Phase 1 Clinical Trial In Cancer Patients 12/9/2014
bluebird bio (BLUE) Announces Data Demonstrating First Four Patients With ß-Thalassemia Major Treated With LentiGlobin® Are Transfusion-Free 12/9/2014
Agios Pharmaceuticals (AGIO) Reports Positive Phase 1 Data In Healthy Volunteers For AG-348, A First-In-Class Investigational Medicine That Targets The Underlying Cause Of Pyruvate Kinase (PK) Deficiency 12/9/2014
Seattle Genetics, Inc. (SGEN) Presents Data From Novel Antibody-Drug Conjugate SGN-CD33A At American Society of Hematology Annual Meeting 12/9/2014
Calithera Biosciences, Inc. (CALA) Presents Preclinical Study Findings For CB-839 At The 56th American Society of Hematology Annual Meeting 12/9/2014
Karyopharm Therapeutics (KPTI) Presents Positive Combination Data For Selinexor (KPT-330) In Multiple Myeloma Patients At American Society of Hematology 2014 Annual Meeting 12/9/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Presentation Of Positive Updated Results From Ongoing MD Anderson-Sponsored Trial Of Vosaroxin In AML And High-Risk MDS At American Society of Hematology Annual Meeting 12/9/2014
Karyopharm Therapeutics (KPTI) Presents Positive Clinical Data For Selinexor (KPT-330) In NHL Patients At American Society of Hematology 2014 Annual Meeting 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Preliminary Data From Ongoing Phase I/II Dose Escalation Study Of TG-1101 (Ublituximab) In Combination With TGR-1202 In Heavily Pre-Treated Relapsed/Refractory B-Cell Malignancies Demonstrates Encouraging Clinical Activity And Safety 12/9/2014
Idera Pharmaceuticals, Inc. (IDRA) Presents Data Supporting IMO-8400 As Novel Therapy For Genetically Defined Forms Of B-Cell Lymphoma At Annual American Society of Hematology Meeting 12/9/2014
Acetylon Pharmaceuticals Announces Ricolinostat Continues To Demonstrate Clinically Meaningful And Durable Disease Response Rates In Phase 1b Combination Studies In Multiple Myeloma 12/9/2014
Jazz Pharmaceuticals (JAZZ) And Concert Pharmaceuticals, Inc. (CNCE) Provide JZP-386 Program Update 12/9/2014
Alnylam Pharmaceuticals (ALNY) Reports Positive Initial Results For ALN-AT3, An Investigational RNAi Therapeutic Targeting Antithrombin (AT) For The Treatment Of Hemophilia And Rare Bleeding Disorders, From Ongoing Phase 1 Trial 12/9/2014
Sevion Therapeutics Presents Results Of SNS01-T Phase 1b/2a Dose Escalation Study At American Society of Hematology Annual Meeting 12/9/2014
Infinity Pharmaceuticals Inc. (INFI) Reports New Results From Phase 1 Study Of Investigational Oncology Compound Duvelisib At The American Society of Hematology Annual Meeting 12/9/2014
Juno Therapeutics’s CAR T and TCR Investigational Product Candidates Demonstrate Promising Outcomes In Clinical Trials In Patients With B-Cell Cancers 12/9/2014
Epizyme (EPZM) DOT1L Inhibitor EPZ-5676 Shows Clinical And Biological Activity In Adult Patients With Acute Leukemias In Phase 1 Trial 12/9/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Long-Term Safety And Efficacy Data Of Ponatinib In Chronic-Phase Chronic Myeloid Leukemia From Phase 1 Clinical Trial 12/9/2014
Ariad Pharmaceuticals, Inc. (ARIA) Announces Follow-Up Data From Phase 1 And PACE Trials Of Ponatinib In Patients With T315I Mutation In Chronic Myeloid Leukemia 12/9/2014
TG Therapeutics, Inc. (MHA) Release: Interim Data From Phase 1 Dose Escalation Clinical Trial Of TGR-1202, The Once-Daily PI3K Delta Inhibitor, Demonstrates Significant Clinical Activity And Lack Of Hepatic Toxicity In Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia And Non-Hodgkin's Lymphoma 12/8/2014
Cornerstone Pharmaceuticals, Inc. Commences Phase I Clinical Trial Of CPI-613 For The Treatment Of B-Cell Non-Hodgkin Lymphoma 12/8/2014
Cellerant Therapeutics, Inc. To Present Phase 1 Clinical Data On Evaluation Of CLT-008 In Patients With Acute Myeloid Leukemia At The 2014 American Society of Hematology Annual Meeting 12/8/2014
Agios Pharmaceuticals (AGIO) Announces New Data From Ongoing Phase 1 Trial Of AG-221 Showing Robust Clinical Activity In Patients With Advanced Hematologic Malignancies 12/8/2014
MorphoSys AG And Xencor Publish Final Results From Phase 1/2a Trial Of MOR208 (Xmab5574) In CLL/SLL At Xencor Annual Meeting 12/8/2014
VaxInnate Corporation Initiates Phase 1b/2 Clinical Trial Of Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, In Elderly 12/8/2014
Affimed Therapeutics AG (AFMD) Presents Final Data For AFM13 Phase 1 Trial At American Society of Hematology 12/8/2014
NKT Therapeutics Inc. Presents Data On Its Therapeutic Program Targeting Sickle Cell Disease At The American Society of Hematology 12/8/2014
Henry Ford Hospital Recruiting Patients For Clinical Trial Which Showed Promising Overall Survival In Recurrent Brain Cancer Patients 12/8/2014
Infinity Pharmaceuticals Inc. (INFI) Reports New Translational Research And Updated Phase 1 Data Of Investigational Oncology Compound Duvelisib At American Society of Hematology Annual Meeting 12/8/2014
Seattle Genetics, Inc. (SGEN) Highlights Multiple ADCETRIS® (Brentuximab Vedotin) Data Presentations In Frontline And Salvage Hodgkin Lymphoma At American Society of Hematology Annual Meeting 12/8/2014
Alnylam Pharmaceuticals (ALNY) Files Clinical Trial Application (CTA) For ALN-CC5, An Rnai Therapeutic Targeting Complement C5 In Development For The Treatment Of Complement-Mediated Diseases 12/8/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data Show Idarucizumab* Reverses Anticoagulant Effects Of Dabigatran (PRADAXA) In Middle-Aged, Elderly And Renally Impaired Volunteers 12/8/2014
Nordic Nanovector Presented Phase I Study Data Reporting Promising Clinical Activity In Patients With Relapsed Non-Hodgkin Lymphoma At American Society of Hematology 12/8/2014
Seattle Genetics, Inc. (SGEN) Presents Data From SGN-CD19A Antibody-Drug Conjugate At American Society of Hematology Annual Meeting 12/8/2014
Triphase Accelerator Announces Its Proteasome Inhibitor Marizomib Demonstrates Potent Synergistic Anti-Multiple Myeloma Activity In Combination With Pomalidomide 12/8/2014
Bristol-Myers Squibb Company (BMY) Release: Opdivo (nivolumab) Demonstrates High Overall Response Rate Of 87% for Treatment Of Relapsed Or Refractory Hodgkin Lymphoma 12/8/2014
ImmunoGen, Inc. (IMGN) Announces Encouraging IMGN529 Clinical Data Presented At 56th American Society of Hematology Annual Meeting and Exposition 12/8/2014
Cellular Biomedicine Group (CBMG) Releases Positive 48-Week Data From Phase I/2a Clinical Trial For Rejoin(TM) Treatment Of Knee Osteoarthritis (KOA) 12/5/2014
OncoSec Medical Inc. Reports ImmunoPulse May Prolong Survival Based On Analysis Of Long-Term Survival Data From Phase I Study In Melanoma 12/5/2014
Five Prime Therapeutics, Inc. (FPRX) Initiates Patient Dosing In Phase 1 Clinical Trial Evaluating FPA144 In Gastric Cancer 12/5/2014
Bavarian Nordic (BAVA.CO) Announces First Subject Dosed With Mva-Bn Filo In A Phase 1 Study Investigating A New Prime-Boost Regimen Of Ebola Candidate Vaccines 12/4/2014
University of Michigan To Study GlycoMimetics, Inc. (GLYC)’ GMI-1271 As Potential Treatment For Serious Blood-Clotting Disorder 12/4/2014
VAXIMM Reports Positive Follow-On Data From Oral Cancer Vaccine Trial 12/4/2014
Set Point Medical Announces First Trial Of Bioelectronic Therapy To Treat Crohn’s Disease 12/4/2014
Cara Therapeutics, Inc. (CARA) Announces Positive Top-Line Results From Phase 1a / 1b Trial Of Tablet Formulation Of Oral CR845 For The Treatment Of Acute And Chronic Pain 12/3/2014
Rhizen Pharmaceuticals S.A. To Present Phase 1 Clinical And Additional Preclinical Data Of RP6530 (Dual PI3K Delta/Gamma Inhibitor) In Hematological Malignancies 12/3/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Nab-Paclitaxel And Gemcitabine In Advanced Pancreatic Cancer 12/3/2014
Syntethic Biologics, Inc. Announces First Patient Dosed In Phase 1a Clinical Trial Of SYN-004 For The Prevention Of C. Difficile Infection 12/2/2014
CollPlant Launched A Clinical Trial With VergenixFG; A Gel Based On A Human Collagen For The Treatment Of Chronic Wounds 12/2/2014
AstraZeneca PLC (AZN) And Eli Lilly (LLY) Move Alzheimer's Drug Into Big Trial 12/1/2014
Momenta Pharmaceuticals, Inc. (MNTA)' Necuparanib Receives Fast Track Designation From The FDA For The Treatment Of Patients With Metastatic Pancreatic Cancer 12/1/2014
Dynavax Technologies Corporation (DVAX) Regains Full Rights To Investigational TLR 7/9 Inhibitor DV1179 Following Expiration Of Collaboration With GlaxoSmithKline (GSK) 12/1/2014
GlaxoSmithKline (GSK), NIH Report Positive Ebola Vaccine Phase 1 Trial 12/1/2014
Novartis AG (NVS) Fires Scientist Who Falsified Data In 6 Research Papers 12/1/2014
Ampio Pharmaceuticals, Inc. (AMPE) Announces Results Of The Open Label Portion Of The Multiple Intra-Articular Injections (STRUT) Study Of Ampion In Patients With Osteoarthritis Of The Knee At Week Twenty Of The Trial 12/1/2014
Karyopharm Therapeutics (KPTI) Announces Additional Orphan Designations Granted For Selinexor (KPT-330) By European Commission (EC) 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 12/1/2014
Takeda Pharmaceuticals’s Investigational, Oral Proteasome Inhibitor Ixazomib Granted Breakthrough Therapy Designation By U.S. FDA For Relapsed Or Refractory Systemic Light-Chain Amyloidosis 12/1/2014
TG Therapeutics, Inc. (MHA) Announces Collaboration For A Clinical Trial Of TGR-1202 In Combination With Ibrutinib (Imbruvica) For Patients With Select B-Cell Malignancies 12/1/2014
Unum Therapeutics Announces Start Of First Phase I Clinical Trial Of Cellular Immunotherapy Targeting CD20+ Chronic Lymphocytic Leukemia And Non-Hodgkin Lymphoma 12/1/2014
Data Published By Researchers From Leading Cancer Institutes Show Polaris Group Lead Therapeutic Candidate ADI-PEG 20 Causes Tumor Cytotoxicity Through Previously Unidentified Mechanism 12/1/2014
ABIVAX Successfully Completes First-In-Man Study Of ABX464, A Highly Differentiated Small Molecule Targeting HIV 12/1/2014
Ablynx (ABLYF) Demonstrates Bioequivalence Between Liquid And Lyophilised Formulations Of Its Anti-Vwf Nanobody, Caplacizumab 11/26/2014
Synthon Initiates Treatment Of First Patients In Phase I Trial Of Anti-HER2 ADC SYD985 Based On Its Proprietary Linker-Drug Platform 11/25/2014
$1 Billion Oncology Alliance Between Menarini Group & Oxford BioTherapeutics Initiates First-In-Human Study Of Enhanced Antibody For Treatment Of Acute Myeloid Leukemia 11/25/2014
Juno Therapeutics T Cell Therapy For Leukemia Granted FDA Breakthrough Therapy Designation 11/25/2014
Catabasis Pharmaceuticals, Inc. Receives FDA Orphan Drug Designation For CAT-1004 For The Treatment Of Duchenne Muscular Dystrophy 11/24/2014
INSYS Therapeutics Receives FDA Orphan Drug Designation For Its Pharmaceutical Cannabidiol As A Potential Treatment For Pediatric Schizophrenia 11/24/2014
Synthetic Biologics, Inc. (SYN) Safe-To-Proceed Under IND To Initiate Clinical Trials Of SYN-004 For The Prevention C. Difficile Infection 11/24/2014
Transition Therapeutics Inc. (TTH.TO)' ELND005 Showed No Prolongation Of QT Interval 11/24/2014
Sprout Pharmaceuticals Presents Phase 1 Clinical Trial Data Showing Treatment With Flibanserin Results In No Next-Day Driving Impairment 11/24/2014
OncoMed Pharmaceuticals, Inc. (OMED) Presents New Clinical And Biomarker Data From Its Tarextumab And Demcizumab Clinical Trials At The European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research Symposium 11/24/2014
Avaxia Biologics, Inc. Receives FDA Orphan Drug Designation For AVX-470 For The Treatment Of Pediatric Ulcerative Colitis 11/21/2014
Intra-Cellular Therapies, Inc. Announces Additional Results From Phase I/2 Clinical Trial For ITI-007 In Healthy Geriatric Subjects And Patients With Dementia 11/21/2014
Phase 1 Dose Escalation Data For Epizyme (EPZM) EZH2 Inhibitor EPZ-6438 (E7438) Shows Single Agent Activity In B-Cell Non-Hodgkin Lymphomas And Malignant Rhabdoid Tumor 11/20/2014
Mirna Therapeutics, Inc. Presents Interim Phase 1 Data On First-In-Class Microrna-34 Mimic, MRX34, At The 26th EORTC-NCI-AACR Symposium On Molecular Targets And Cancer Therapeutics 11/20/2014
Transition Therapeutics Inc. (TTH.TO) Announces Results From ELND005 Clinical Study In Adults With Down Syndrome 11/20/2014
St. Jude Children's Research Hospital Release: Gene Therapy Provides Safe, Long-Term Relief For Patients With Severe Hemophilia B 11/20/2014
DBV Technologies Initiates Phase I/2 Clinical Trial With Viaskin Milk For The Treatment Of Children With Cow's Milk Allergy 11/20/2014
Themis Bioscience’s Vaccine Against Chikungunya Successful In Phase 1 11/20/2014
Marina Biotech, Inc. (MRNA) Reports That Partner Mirna Therapeutics, Inc. Presented Interim Phase 1 Data On Its First-in-Class microRNA-34 Mimic 11/20/2014
Omni Bio Pharmaceutical Announces Presentation Of Phase 1/2 Clinical Data For AAT At American Heart Association Scientific Sessions 11/20/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Pemetrexed And Cisplatin In Malignant Pleural Mesothelioma And Non-Squamous Non-Small Cell Lung Carcinoma 11/20/2014
Cempra To Receive Biomedical Advanced Research and Development Authority (BARDA) Funding For 1b And Start-Up Of Phase 2/3 Solithromycin Pediatric Studies 11/19/2014
Sunesis Pharmaceuticals, Inc. (SNSS) Announces Publication Of Vosaroxin Phase 1b/2 AML Trial Results In Haematologica 11/19/2014
Otologic Pharmaceutics Initiates Phase 1 Clinical Study Of HNPN-1010 For Hearing Disorders 11/19/2014
PTC Therapeutics, Inc. (PTCT) Release: Spinal Muscular Atrophy Program Enters Phase 1b/2a Trial In Patients With SMA 11/19/2014
BerGenBio AS Receives Orphan-Drug Designation From FDA For BGB324 In The Treatment Of Acute Myeloid Leukaemia 11/19/2014
THERAVECTYS Provides Update On Its Phase 1/2 Lentiviral Vector-Based Therapeutic Vaccine Trial 11/19/2014
Omni Bio Pharmaceutical Announces Phase 1/2 Clinical Data Of AAT In Myocardial Infarction At American Heart Association Scientific Session 11/19/2014
Clovis Oncology (CLVS) Release: Interim Data From Rociletinib (CO-1686) Phase 1/2 Study Shows Compelling And Durable Clinical Activity And Progression-Free Survival (PFS) In Patients With EGFR-Mutant Non-Small Cell Lung Cancer (NSCLC) 11/19/2014
OncoMed Pharmaceuticals, Inc. (OMED) Presents Biomarker-Focused Clinical Data From Phase 1a Trial Of Anti-Notch1 (OMP-52M51) In Oral Plenary Session At The 26th OncoMed Pharmaceuticals, Inc. (OMED)-European Organization for Research and Treatment of Cancer-National Cancer Institute Symposium 11/19/2014
Threshold Pharmaceuticals, Inc. (THLD) Announces Phase 1/2 Interim Data Signaling Activity Of TH-302 Plus Bevacizumab (Avastin(R)) In Patients With Glioblastoma 11/19/2014
3-V Biosciences Announces Presentation Of First Human Clinical Data For Lead Oral FASN Inhibitor Candidate At European Organization for Research and Treatment of Cancer-National Cancer Institute-American Association for Cancer Research 2014 11/19/2014
MabVax Therapeutics, Inc. And Memorial Sloan-Kettering Cancer Center Report On Potential Use Of Dual-Labeled Antibody To Detect And Guide Surgical Removal Of Pancreatic Cancer 11/19/2014
Juno Therapeutics's JCAR015 Leukemia T Cell Therapy Granted Orphan Drug Designation By FDA 11/18/2014
Capricor Therapeutics, Inc. Announces Favorable ALLSTAR Phase I Safety Results 11/18/2014
Polaris Group Announces Treatment Of First Patient In Phase 1 Study Of ADI-PEG 20 Plus Doxorubicin In HER2 Negative Breast Cancer 11/18/2014
Arrowhead Research Corporation (ARWR) Files For Regulatory Permission To Begin Phase 1 Trial Of RNAi Therapeutic ARC-AAT 11/18/2014
GlycoMimetics, Inc. (GLYC) Announces Positive Top-Line Results From Phase 1 Study Of GMI-1271 In Healthy Volunteers 11/18/2014
Boehringer Ingelheim Pharmaceuticals, Inc. Release: New Data Show Idarucizumab* Restores Wound-Site Formation Of Fibrin, A Key Component Of Blood Clotting, In Healthy Volunteers Given Pradaxa (dabigatran etexilate mesylate) 11/18/2014
The Lancet Neurology Publishes Prana’s Huntington Disease Trial 11/18/2014
Agios Pharmaceuticals (AGIO) Announces Early Phase 1 Data Showing Clinical Activity Of AG-120 As A Single Agent In Advanced Acute Myeloid Leukemia (AML) 11/18/2014
NeuralStem Inc. NSI-189 Phase Ib Major Depression Disorder Neurogenic Biomarker Data Presented At The CNS Summit 11/17/2014
AbbVie (ABBV) Presents Results From Study Of ABT-414 In Patients With Glioblastoma Multiforme At The 19th Annual Scientific Meeting And Education Day Of The Society For Neuro-Oncology 11/17/2014
Anavex Life Sciences Corp. (AVXL.OB) Announces Positive Phase 1 Data For ANAVEX 2-73, Lead Candidate For The Treatment Of Alzheimer's 11/17/2014
Deciphera Pharmaceuticals Presents Data On Altiratinib (DCC-22701) That Demonstrated Inhibition Of Tumor Growth And Invasion In Bevacizumab Resistant Glioblastoma 11/17/2014
CONRAD Launches First-Ever Multipurpose Vaginal Ring Clinical Trial 11/17/2014
The Medicines Company (MDCO) Presents New Phase 1 Data Showing Investigational Agent MDCO-216 Modified Key Lipid Parameters And Was Well-Tolerated In Healthy And Coronary Artery Disease (CAD) Patients 11/17/2014
DelMar Pharmaceuticals' Promising New Data Support The Potential Of VAL-083 To Meet Significant Unmet Medical Needs In The Treatment Of Glioblastoma Multiforme 11/17/2014
Hemispherx Biopharma (HEB) Release: Ampligen(R) Blocks Critical Ebola Viral Disease (EVD) Protein Which Is Linked To High Mortality In Man 11/17/2014
Protalex, Inc. (PRTX) Announces Data From Phase 1b Trial Of PRTX-100 In Patients With Active Rheumatoid Arthritis Treated For Longer Duration Shows Safety And Reduction In Disease Activity 11/17/2014
Allena Pharmaceuticals, Inc. Presents Phase 1 Data On ALLN-177 A American Society of Nephrology Kidney Week 2014 11/17/2014
Exelixis, Inc. (EXEL) Announces Positive Preliminary Data From An Investigator-Sponsored Phase 1 Trial Of XL888 And Vemurafenib 11/17/2014
Relypsa, Inc. (RLYP) Announces Key Data Presented At American Society of Nephrology On Long-Term Chronic Treatment And Early Onset Of Action With Patiromer For Oral Suspension 11/17/2014
Five Prime Therapeutics, Inc. (FPRX) Initiates Dosing Of Rheumatoid Arthritis Patients In Its Phase 1 Clinical Trial Of FPA008 11/17/2014
Cortice Biosciences Announces Initial Results From A Phase 1/2 Clinical Trial Evaluating TPI 287 For Treatment Of Recurrent Glioblastoma 11/14/2014
Five Prime Therapeutics, Inc. (FPRX) To Present Data From Healthy Volunteer Cohorts In Phase 1 Trial Of FPA008 At The 2014 American College of Rheumatology/ARHP Annual Scientific Meeting 11/14/2014
Canadian Institutes Of Health Research Release: Canada Begins Ebola Vaccine Trial 11/14/2014
FlexPharma Presents Results From Three Human Clinical Studies 11/14/2014
Cell Source's Megadose Drug Combination Receives Regulatory Approval In Italy To Commence Human Clinical Trials 11/13/2014
MaxiVAX SA Release: Swiss Biotech Starts Breakthrough Anti-Cancer Clinical Trial Based On Active Immunotherapy 11/13/2014
GliaCure's Lead Product, GC021109, Receives FDA Fast Track Designation 11/12/2014
Matinas BioPharma Commences Dosing In First Human Trial Of Lead Product Candidate MAT9001 11/12/2014
Advaxis, Inc. Submits Investigational New Drug Application For Phase 1/2 Study Of ADXS-HPV And Medimmune's MEDI4736 For The Treatment Of HPV-Associated Cervical And Head & Neck Cancer 11/12/2014
Oncoethix Starts Phase 1b Trials Of OTX015 In The Treatment Of Advanced Solid Tumors (OTX015_107) And Glioma (OTX015_108) 11/12/2014
VaxInnate Corporation Quadrivalent Seasonal Influenza Vaccine Candidate, VAX2012Q, Meets Phase 1 Seasonal Influenza Endpoints 11/11/2014
Bionomics Limited (BNO.AX) To Progress BNC210 In Clinical Trials 11/11/2014
Oncothyreon Inc. (ONTY) And Celldex Therapeutics, Inc. (CLDX) Announce Initiation Of Combination Immunotherapy Clinical Trial Of ONT-10 And Varlilumab 11/11/2014
ProMetic Life Sciences Inc. (PFSCF.PK)'s PBI-4050 Cleared To Commence Clinical Trials In Patients With Diabetic Kidney Disease 11/11/2014
MA Startup SAGE Therapeutics' Drug For Rare Epilepsy Shows Promise In Small Study 11/10/2014
SAGE Therapeutics Reports Positive Top-Line Phase 2 Data of SAGE-547 in Patients With Super-Refractory Status Epilepticus 11/10/2014
Novavax, Inc. (NVAX) Initiates Phase 1 Clinical Trial Of RSV F Vaccine In Pediatric Subjects 11/10/2014
Galectin Therapeutics' Phase 1 Data Presented At American Association for Study of Liver Diseases Annual Meeting Advances GR-MD-02 Into Phase 2 Clinical Development 11/10/2014
Anavex Life Sciences Corp. (AVXL.OB) To Present Full Phase 1 Clinical Trial Data For ANAVEX 2-73 At CNS Summit 2014 Conference 11/10/2014
NeuralStem Inc. Announces Publication Of Long Term Cell Survival From Phase I NSI-566 ALS Study In The Journal "Annals Of Clinical And Translational Neurology" 11/10/2014
EnGeneIC Pty Ltd And Asbestos Diseases Research Institute Initiate Mesomir-1 Phase 1 Trial In Patients With Late Stage Mesothelioma 11/10/2014
Novira Therapeutics Announces Presentation Of Phase 1a Safety And Pharmacokinetic Data For NVR 3-778 11/10/2014
Eagle Pharmaceuticals (EGRX) Reports Positive Outcomes From Clinical Trial Of Bendamustine HCl Product Delivered Via Low-Volume, Rapidly Infused Admixture 11/10/2014
R-Tech Ueno: Completion Of A Phase I/II Clinical Study Of Recombinant Human Serum Albumin-Containing Ophthalmic Solution (Development Code: RU-101) In The U.S. For The Treatment Of Severe Dry Eye 11/10/2014
Seattle Children's Research Institute's Begins Recruiting Patients For Immunotherapy Research Trial For Neuroblastoma, One Of The Deadliest Forms Of Childhood Cancer 11/7/2014
Merrimack Pharmaceuticals Inc. (MACK) Announces Initiation Of Phase 1 Clinical Study Of MM-398 For Brain Cancer 11/6/2014
Perosphere Inc.’s Anticoagulant Reversal Agent Clinical Trial Results Published In The New England Journal of Medicine 11/6/2014
Cornerstone Pharmaceuticals, Inc. Announces Positive Phase I Data For CPI-613 In Relapsed Or Refractory AML Patients To Be Presented At 2014 American Society of Hematology Annual Meeting 11/6/2014
Epizyme (EPZM) Reports Publication Of Preliminary Findings from Phase 1 Study Of DOT1L Inhibitor EPZ-5676 In American Society of Hematology Annual Meeting Abstract 11/6/2014
FDA Grants Orphan Drug Designation To Merrimack Pharmaceuticals Inc. (MACK)' MM-141 For The Treatment Of Pancreatic Cancer 11/5/2014
BioLineRx Ltd. Announces Successful Final Results Of Phase 1/2 Study For Novel Celiac Treatment 11/5/2014
Ruthigen Announces First Patient Enrollment In The Phase 1/2 Human Clinical Trial Of RUT58-60, A Broad-Spectrum Anti-Infective Drug Candidate Designed For Prophylactic Use During Invasive Surgery 11/4/2014
BerGenBio AS Announces First Patient Dosed in BGB324 AML Trial 11/4/2014
Edge Therapeutics Initiates Enrollment Of Third Cohort In Phase 1/2 NEWTON Study Of EG-1962 For Improvement Of Outcome After Ruptured Brain Aneurysm 11/4/2014
Theravance Biopharma Announces Positive Results From Phase 1 Proof-of-Concept Study Of TD-6450, An NS5A Inhibitor To Treat Hepatitis C 11/4/2014
Que Oncology Announces Positive Phase 1 Results With Q-122 11/4/2014
SAGE Therapeutics Release: First Evaluation Of SAGE-547 To Treat Super-Refractory Status Epilepticus In Children Published In Annals Of Neurology 11/3/2014
MorEx Extends Phase I MTL-005 Radiation Enhancer Head & Neck Cancer Trial 11/3/2014
Suven Life Sciences Ltd Release: SUVN-G3031 For Cognition In Alzheimer’s Disease Commenced Phase 1 Clinical Trial In U.S.A. Under US-IND 123179 11/3/2014
Kolltan Pharmaceuticals Inc. Begins Phase 1b Cancer Study Evaluating KTN3379 In Combination With Multiple Targeted Therapies At Sarah Cannon Research Institute 11/3/2014
Dyax Corp. (DYAX) Announces Expansion Of Phase 1b Clinical Trial For DX-2930 11/3/2014
Xcovery Presents Phase 1 Results Of X-396 In ALK Positive NSCLC At The 2014 Multidisciplinary Symposium In Thoracic Oncology 10/31/2014
NovoCure Ltd. Enrolls First Patient In A Pilot Study Of Tumor Treating Fields (TTFields) Together With Paclitaxel For The Treatment Of Recurrent Ovarian Cancer 10/30/2014
Hemispherx Biopharma (HEB) Reports New Evidence -- Based Potential Of Ampligen® Against Ebola Virus Disease (EVD) 10/30/2014
FDA Grants Fast Track Designation To Novavax, Inc. (NVAX)' H7N9 Influenza Virus-Like Particle Vaccine Candidate Adjuvanted With Matrix-M™ 10/30/2014